Major Drug Recalls: Dr. Reddy's and Lupin Face Manufacturing Issues

Dr. Reddy's Laboratories and Lupin are recalling products in the US due to manufacturing issues identified by the USFDA. Dr. Reddy's is recalling over 150,000 bottles of Ibuprofen, while Lupin is recalling 4,554 bottles of Cefixime due to subpotency. Both recalls are classified as Class II, indicating non-serious adverse consequences.

Dr. Reddy's Laboratories and Lupin are pulling back their pharmaceutical products from the US market, following manufacturing deficiencies highlighted by the US Food and Drug Administration (USFDA).

According to the latest USFDA enforcement report, Dr. Reddy's Laboratories Inc., a New Jersey-based subsidiary of the Hyderabad-origin firm, has initiated a recall of Ibuprofen tablets in multiple strengths. Over 150,000 bottles have been called back due to impurities exceeding permissible limits.

Lupin Pharmaceuticals Inc., based in Baltimore and linked to the Mumbai-headquartered company, is also recalling 4,554 bottles of Cefixime for Oral Suspension. The drug, used to tackle bacterial infections, was deemed subpotent. Both recalls are categorized as Class II, entailing potential yet non-serious health risks.

(With inputs from agencies.)